- Conditions
- Colorectal Cancer
- Interventions
- 5-fluorouracil, Cetuximab, Irinotecan, Leucovorin, MEHD7945A
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 210
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab, Trifluridine-tipiracil
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,917 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2008
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
- Conditions
- Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure
- Interventions
- BMX-001
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Stage III Colon Cancer
- Interventions
- Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
- Device · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1037
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- FOLFIRI, AMG 655, Placebo, AMG 479
- Other · Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more
- Conditions
- Pancreatic Cancer
- Interventions
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Rectal Adenocarcinoma
- Interventions
- Capecitabine, Radiation Therapy, FOLFOX regimen
- Drug · Radiation
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Central Nervous System Malignancies, Ependymoma
- Interventions
- 5-fluorouracil
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
- Interventions
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride, 5-FU
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Solid Tumors
- Interventions
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid, 5-Fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio + 2 more
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Interventions
- Lidocaine Hydrochloride, Placebo, FOLFOX regimen
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colon Cancer, Rectal Cancer
- Interventions
- FOLFIRI, E7820
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • West Palm Beach, Florida • Atlanta, Georgia + 3 more
- Conditions
- Colorectal Cancer
- Interventions
- Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab, Panitumumab
- Drug
- Lead sponsor
- Nicholas DeVito, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Solid Tumor Malignancies
- Interventions
- PD-0332991, 5-FU, Oxaliplatin
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Gastrointestinal Cancer
- Interventions
- Oxaliplatin (SR96669)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
- Conditions
- Colorectal Cancer
- Interventions
- Ramucirumab, Placebo, Irinotecan, Folinic Acid, 5-Fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 92
- States / cities
- Sedona, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 89 more
- Conditions
- Colon Cancer
- Interventions
- Vigil™ Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
- Interventions
- Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Drug · Radiation · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
- Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Bladder Cancer
- Interventions
- cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more
- Conditions
- Gastric Cancer
- Interventions
- Bemarituzumab, Placebo, Modified FOLFOX6
- Biological · Drug
- Lead sponsor
- Five Prime Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more